NCT03968653 - Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

Debio 0123

Debio 0123 will be given as an oral capsule for 3 days during each 21-day cycle, except Cycle 1 which is of 24 days.

DRUG

Carboplatin

Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 2 onwards in Group A.

DRUG

Debio 0123

Debio 0123 will be given as an oral capsule for 3 or 6 days during each 21-day cycle.

DRUG

Carboplatin

Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 1 onwards.

Trial Locations (8)

Leiden University Medical Center, Dept. of Clinical Oncology, Leiden

Radboud university medical center, Nijmegen

University Medical Center Groningen, Groningen

Clinica Universidad de Navarra, Madrid

Hospital Universitario Virgen de la Victoria, Málaga

Clinica Universidad de Navarra - Pamplona, Pamplona

Instituto Valenciano de Oncologia, Valencia

Hospital Vall Hebrón, Unidad de Investigación en Terapia Molecular (UITM), Barcelona